Menu Search
Equities

CRISM' Therapeutics Corp

A7L:STU

CRISM' Therapeutics Corp

Actions
  • Price (EUR)2.24
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jun 01 2023.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

CRISM Therapeutics Corporation, formerly Amur Minerals Corporation, is a British Virgin Islands-based pharmaceutical company. The Company has developed a drug delivery technology, ChemoSeed, to improve the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy. Its lead product, ChemoSeed, is a polymer the size of a grain of rice, administering irinotecan, a generic drug approved to treat brain cancer and can be implanted directly into a tumor or the resection margin following the removal of a tumor, thereby ensuring that effective therapeutic concentrations of chemotherapy drugs directly reach the tumor tissue. It seeks to use ChemoSeed to treat high grade gliomas, a brain tumor with no satisfactory treatment. The Company also offers formulation and consultancy services. It provides assistance and services to improve the bioavailability of poorly soluble drugs. It offers remixers and extruders of various sizes.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-1.79m
  • Incorporated2004
  • Employees4.00
  • Location
    CRISM' Therapeutics CorpKingston Chambers,, Road TownPO Box 173TORTOLA 680063Virgin Islands (British)VGB
  • Phone+7 4 212755615
  • Websitehttps://www.crismtherapeutics.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		CRTX:LSE since
announced		Transaction
value
Extruded Pharmaceuticals LtdAnnounced13 May 202413 May 2024Announced-23.61%--
Data delayed at least 20 minutes, as of Sep 20 2024 15:45 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.